OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector (the “Company”) announces that the subscription period for the subsequent repair offering (the “Offering”) of up to 2,000,000 new shares at a subscription price of NOK 25 per share, ended on 12 September 2014 at 16:00 CET.
The Offering was oversubscribed. Final result of the Offering is expected to be announced on or about 16 September 2014. Allocation letters giving notification of allocated new shares and the corresponding subscription amount to be paid by each subscriber will be sent on or about the same day. Only shareholders of the Company as of 27 June 2014 (registered as such in the Norwegian Central Securities Depository (the “VPS”) on 2 July 2014 pursuant to the three days’ settlement procedure in VPS), will be allocated shares in the Offering.
ABG Sundal Collier and DNB Markets acted as managers for the Offering.
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
This information was brought to you by Cision http://news.cision.com